Trevor Richter | Director, Common Drug Review and Optimal Use
CADTH

Trevor Richter, Director, Common Drug Review and Optimal Use, CADTH

Trevor joined CADTH in 2010 as a Clinical Research Officer, and was quickly promoted to Clinical Research Manager. While at CADTH, Trevor has expanded his health technology assessment and drug review experience by completing assignments with our health economics and medical device portfolios. Trevor holds a PhD in neuroscience from the University of Cambridge and an MSc in physiology from the University of Pretoria

Appearances:



World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

CANADA: Orphan drug evaluation and decision making in Canada in the context of international HTA decisions

  • Orphan drug evaluation at CADTH to reimburse, reimburse with clinical criteria/conditions and not reimburse
  • HTA challenges when there is no regulatory framework for orphan drugs in Canada and no international consensus for OD
  • Balancing evidence requirements with treatment’s cost 

back to speakers